PAREXEL Launches Next Generation Analytics Capabilities Within Perceptive MyTrials Platform
BOSTON, MA, July 21, 2015 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched the next generation of its Perceptive MyTrials® platform with advanced analytics capabilities. With the Perceptive MyTrials Analytics solution, clinical trial sponsors can now use a mobile-enabled, single entry-point to access predictive data analytics for multiple studies simultaneously. The solution offers real-time and aggregated analytics allowing sponsors and PAREXEL® clinical research professionals to detect key signals and trends. The Perceptive MyTrials Analytics solution also offers cross-sponsor viewing options for clients who need to evaluate data from multiple sponsors.
“As clinical studies become more complex, there is a growing need for real-time and standardized data and analytics from multiple studies,” said Xavier Flinois, President, PAREXEL Informatics. “Using the enhanced tools available with the Perceptive MyTrials Analytics solution, our clients can visualize trends across studies, garner reliable intelligence, and confidently make
Developed by PAREXEL Informatics, the Perceptive MyTrials® platform provides an integrated suite of applications for managing clinical trials. Perceptive MyTrials Analytics offers enhanced analytics capabilities and cross-study business intelligence from within the Perceptive MyTrials platform.
Flinois added, “At PAREXEL, our mission is to bring science to the real world by simplifying a client’s journey at every step. Perceptive MyTrials Analytics is another example of the integrated solutions we are developing that incorporate optimized
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025